Clinical Trial Update: A Study to Evaluate the Safety and Tolerability of Long-term Administration of Gantenerumab in Participants With Alzheimer's Disease (AD) [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating long-term safety and tolerability of gantenerumab in Alzheimer's disease has been terminated with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease

Drugs mentioned

• Gantenerumab (gantenerumab)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Alzheimer Disease | Phase 3 | Status: TERMINATED | Results posted: 2024-01-18